ALSO NOTED: Epix appeal fails; FDA questions Gestiva efficacy; and much more...

> Shares of Epix Pharmaceuticals took a sharp downturn after the company announced that the FDA had rejected its appeal for an approval of its blood imaging agent Vasovist. Report

> Agency staffers are questioning the safety and efficacy of Adeza's Gestiva, which is designed to prevent pre-term birth. New data is at odds with a government-funded study and shows a possible rise in miscarriages and still births. An FDA advisory committee meets tomorrow to discuss the drug. Report

> Any notion that the Vatican might condone a new approach to developing embryonic stem cells for medical purposes was quickly nixed by church officials in Rome. Article

> The UK's Switch Pharma has inked a deal to acquire Gardant in a stock swap. Report

> Dr. Reddy's will sell up to $300 million in American Depository Receipts to fund a recent acquisition. Report

> BioMarin has launched OraPred ODT in the U.S. Release

And Finally... One hospital in New York is testing the healing powers of music. Article